Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice
Journal of Clinical and Translational Pathology · 2022
DOI: 10.14218/jctp.2022.00012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Translational Pathology, 2022. Verfasst von Sean M. Hacking und 1 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
For the past several decades, markers of cellular proliferation in breast cancer have been postulated to indicate prognosis and predict benefits from antineoplastic therapies. The most common method to measure cellular proliferation by Ki-67 is immunohistochemistry (IHC) based assays. However, analytical issues have hindered the widespread adoption of these measures in patient care. The recent monarch E clinical trial prospectively investigated Ki-67 as a biomarker of cyclin-dependent kinase inhibitor (CDKI), Abemaciclib in the adjuvant setting. It established the benefit of CDKI in high-risk ER-positive breast cancer patients with Ki-67 expression >20%, which promoted the increased clinical demand for routine Ki-67 testing in pathology laboratories. This review summarizes some recent developments and practical issues for Ki-67 evaluation.
Zitieren
APA
Hacking, S. M., & Wang, Y. (2022). Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice. Journal of Clinical and Translational Pathology. https://doi.org/10.14218/jctp.2022.00012
Vancouver
Hacking SM, Wang Y. Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice. Journal of Clinical and Translational Pathology. 2022. doi:10.14218/jctp.2022.00012
BibTeX
@article{Hacking2022,
author = {Hacking, Sean M. and Wang, Yihong},
title = {Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice},
journal = {Journal of Clinical and Translational Pathology},
year = {2022},
doi = {10.14218/jctp.2022.00012}
}
EUVIMED